Celltrion wins 294.9 bln-won drug substance supply deal from global firm | Yonhap News Agency

## Summary
OK SEOUL, March 17 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical company, said Tuesday it has secured a 294.9 billion-won (US$198 million) contract to supply drug substances to a global pharmaceutical company through 2029. The company currently has a total manufacturing capacity of 316,000 liters, including 250,000 liters at three domestic plants in Songdo, west of Seoul, and 66,000 liters at its U.S. facility in New Jersey. "Considering the need to expand manufacturing for our own products, along with growth in the CDMO business and rising global demand, we plan to actively pursue additional manufacturing capacity to support future growth," a Celltrion official said. This file photo provided by Celltrion Inc. shows a company production plant in Songdo, about 40 kilometers west of Seoul. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles (LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup Celltrion completes acquisition of U.S. biopharmaceutical plant Celltrion to invest 4 tln won to expand domestic facilities Keywords #Celltrion #drug substance supply deal Articles with issue keywords Most Liked 16th Gwangju Biennale: You must change your life (News Focus) USFK's relocation of military assets to Middle East raises concerns about Seoul's capability to deter N.K. threats BTS expands Gwanghwamun concert capacity to 22,000 with added standing zones (2nd LD) N. Korea holds parliamentary elections prev Celltrion wins 294.9 bln-won drug substance supply deal from global firm Next Celltrion wins 294.9 bln-won drug substance supply deal from global firm

## Article Content
Facebook
X
More
Pinterest
Linked in
Tumblr
Reddit
Facebook Messenger
Copy URL
URL is copied.
OK
SEOUL, March 17 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical company, said Tuesday it has secured a 294.9 billion-won (US$198 million) contract to supply drug substances to a global pharmaceutical company through 2029.
The contract value could rise to 375.4 billion won depending on mutual agreement between the two parties, the company said in a press release.
However, the company did not disclose the name of the customer, citing confidentiality.
Celltrion said its contract manufacturing organization (CMO) business has expanded since it announced plans last year to strengthen the segment.
Earlier this year, the company signed a 678.7 billion-won CMO agreement with Eli Lilly and Company (LLY), bringing its cumulative CMO order backlog to more than 1 trillion won within the first quarter of the year.
The deal follows Celltrion's January acquisition of a 460 billion-won manufacturing facility in New Jersey from the U.S. drugmaker through its U.S. subsidiary, Celltrion USA Inc.
Amid rising demand for contract development and manufacturing organization (CDMO) partnerships from global pharmaceutical companies, Celltrion said it is considering expanding its production capacity.
The company currently has a total manufacturing capacity of 316,000 liters, including 250,000 liters at three domestic plants in Songdo, west of Seoul, and 66,000 liters at its U.S. facility in New Jersey.
"Considering the need to expand manufacturing for our own products, along with growth in the CDMO business and rising global demand, we plan to actively pursue additional manufacturing capacity to support future growth," a Celltrion official said.
Celltrion has also been expanding its global biosimilar portfolio, increasing the number of approved products from six to 11. The company aims to commercialize 18 biosimilars by 2030 and 41 by 2038.
Its only original drug, Zymfentra, is currently sold in the United States to treat autoimmune diseases. The product is marketed as Remsima SC in Europe and other regions.
This file photo provided by Celltrion Inc. shows a company production plant in Songdo, about 40 kilometers west of Seoul. (PHOTO NOT FOR SALE) (Yonhap)
kyongae.choi@yna.co.kr
(END)
Related Articles
(LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup
Celltrion completes acquisition of U.S. biopharmaceutical plant
Celltrion to invest 4 tln won to expand domestic facilities
Keywords
#Celltrion
#drug substance supply deal
Articles with issue keywords
Most Liked
16th Gwangju Biennale: You must change your life
(News Focus) USFK's relocation of military assets to Middle East raises concerns about Seoul's capability to deter N.K. threats
BTS expands Gwanghwamun concert capacity to 22,000 with added standing zones
(2nd LD) N. Korea fires ballistic missiles as S. Korea, U.S. conduct joint drills
Police vow zero tolerance for terror threats against BTS comeback concert
Most Saved
16th Gwangju Biennale: You must change your life
(2nd LD) N. Korea fires ballistic missiles as S. Korea, U.S. conduct joint drills
(LEAD) N. Korea fires projectile as S. Korea, U.S. conduct joint drills
S. Korea, U.S. hold joint river-crossing drills amid N. Korea's missile firing
Samsung Biologics, Eli Lilly to establish biotech incubator in Incheon
Most Viewed
All Categories
(LEAD) POSCO Future M wins 1 tln-won battery material supply deal from global automaker
N. Korea estimated to have earned up to US$14.4 bln from Russia-Ukraine war involvement: report
(3rd LD) 'KPop Demon Hunters' wins Oscars for best animated feature, original song
(LEAD) Cheong Wa Dae says sufficient deliberations needed to handle Trump's request for Hormuz warships
(3rd LD) Trump renews calls on S. Korea, China, Japan, others to help keep Strait of Hormuz open
Most Viewed More
Most Viewed Photos
N. Korea holds parliamentary elections
N. Korea holds parliamentary elections
Korean won weakens
N. Korea holds parliamentary elections
prev
Celltrion wins 294.9 bln-won drug substance supply deal from global firm
Next
Celltrion wins 294.9 bln-won drug substance supply deal from global firm

---

## Expert Analysis

### Merits
N/A

### Areas for Consideration
- This file photo provided by Celltrion Inc. shows a company production plant in Songdo, about 40 kilometers west of Seoul. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles (LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup Celltrion completes acquisition of U.S. biopharmaceutical plant Celltrion to invest 4 tln won to expand domestic facilities Keywords #Celltrion #drug substance supply deal Articles with issue keywords Most Liked 16th Gwangju Biennale: You must change your life (News Focus) USFK's relocation of military assets to Middle East raises concerns about Seoul's capability to deter N.K. threats BTS expands Gwanghwamun concert capacity to 22,000 with added standing zones (2nd LD) N.

### Implications
- The contract value could rise to 375.4 billion won depending on mutual agreement between the two parties, the company said in a press release.
- The company currently has a total manufacturing capacity of 316,000 liters, including 250,000 liters at three domestic plants in Songdo, west of Seoul, and 66,000 liters at its U.S. facility in New Jersey. "Considering the need to expand manufacturing for our own products, along with growth in the CDMO business and rising global demand, we plan to actively pursue additional manufacturing capacity to support future growth," a Celltrion official said.
- This file photo provided by Celltrion Inc. shows a company production plant in Songdo, about 40 kilometers west of Seoul. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles (LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup Celltrion completes acquisition of U.S. biopharmaceutical plant Celltrion to invest 4 tln won to expand domestic facilities Keywords #Celltrion #drug substance supply deal Articles with issue keywords Most Liked 16th Gwangju Biennale: You must change your life (News Focus) USFK's relocation of military assets to Middle East raises concerns about Seoul's capability to deter N.K. threats BTS expands Gwanghwamun concert capacity to 22,000 with added standing zones (2nd LD) N.
- Korea, U.S. conduct joint drills Police vow zero tolerance for terror threats against BTS comeback concert Most Saved 16th Gwangju Biennale: You must change your life (2nd LD) N.

### Expert Commentary
This article covers celltrion, korea, won topics. Areas of concern are also raised. Readability: Flesch-Kincaid grade 0.0. Word count: 641.